The Cooper Cos. (NYSE:COO) traded down 1% on Friday . The company traded as low as $182.27 and last traded at $183.52, with a volume of 303,957 shares trading hands. The stock had previously closed at $185.37.

A number of equities research analysts have weighed in on the stock. BMO Capital Markets boosted their target price on shares of The Cooper Cos. from $199.00 to $206.00 and gave the company an “outperform” rating in a research note on Friday. Piper Jaffray Cos. reiterated a “buy” rating on shares of The Cooper Cos. in a research note on Saturday, June 4th. Stephens reiterated a “hold” rating on shares of The Cooper Cos. in a research note on Saturday, June 4th. Stifel Nicolaus reiterated an “in-line” rating on shares of The Cooper Cos. in a research note on Friday. Finally, Jefferies Group reiterated a “buy” rating and set a $190.00 target price (up from $175.00) on shares of The Cooper Cos. in a research note on Thursday, June 2nd. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $177.70.

The stock has a market capitalization of $9.01 billion and a P/E ratio of 43.98. The firm has a 50-day moving average of $181.74 and a 200 day moving average of $163.78.

The Cooper Cos. (NYSE:COO) last issued its earnings results on Thursday, September 1st. The medical device company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.29 by $0.01. The company earned $514.70 million during the quarter. During the same period last year, the firm posted $1.97 EPS. The company’s quarterly revenue was up 11.5% on a year-over-year basis. On average, analysts expect that The Cooper Cos. will post $8.44 earnings per share for the current fiscal year.

The business also recently announced a semiannual dividend, which was paid on Friday, August 5th. Stockholders of record on Friday, July 22nd were issued a $0.03 dividend. This represents a dividend yield of 0.03%. The ex-dividend date was Wednesday, July 20th.

In other news, Director Gary S. Petersmeyer sold 3,000 shares of the company’s stock in a transaction on Tuesday, June 14th. The shares were sold at an average price of $162.51, for a total value of $487,530.00. Following the completion of the transaction, the director now owns 4,715 shares in the company, valued at approximately $766,234.65. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director A Thomas Bender sold 4,000 shares of the company’s stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $164.19, for a total transaction of $656,760.00. Following the completion of the transaction, the director now owns 14,978 shares of the company’s stock, valued at approximately $2,459,237.82. The disclosure for this sale can be found here.

The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.